Study IDs Risk Factors for Violent Sleep Disorder
WEDNESDAY, Dec. 26, 2018 -- Rapid eye movement (REM) sleep behavior disorder (RBD) is more common among men, as well as those with psychological distress, mental illness, or posttraumatic stress disorder, according to a study published online Dec. 26 in Neurology.
Chun Yao, from McGill University in Montreal, and colleagues analyzed data from 30,097 participants (aged 45 to 85 years) in the Canadian Longitudinal Study on Aging. The authors sought to identify sociodemographic, socioeconomic, and clinical factors associated with idiopathic RBD. Participants were excluded from analysis if they had apnea, non-REM parasomnia (young-onset possible RBD [pRBD]), dementia, or Parkinson disease.
The researchers found that 3.2 percent of the study participants had pRBD, which was associated with male sex (odds ratio [OR], 2.09; 95 percent confidence interval [CI], 1.78 to 2.44) and lower education (OR, 0.95; 95 percent CI, 0.92 to 0.98). Additionally, participants with pRBD smoked more (OR, 1.01; 95 percent CI, 1.00 to 1.01) and were more likely to be moderate-to-heavy drinkers (OR, 1.25; 95 percent CI, 1.04 to 1.51). The associations between pRBD and self-reported antidepressant treatment for depression (OR, 2.77; 95 percent CI, 2.23 to 3.45), psychological distress (OR, 1.61; 95 percent CI, 1.44 to 1.80), mental illness (OR, 2.09; 95 percent CI, 1.75 to 2.49), and posttraumatic stress disorder (OR, 2.68; 95 percent CI, 1.97 to 3.65) were all strong.
"Identifying lifestyle and personal risk factors linked to this sleep disorder may lead to finding ways to reduce the chances of developing it," a coauthor said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: December 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.